Hologic, Inc. (HOLX)
Automate Your Wheel Strategy on HOLX
With Tiblio's Option Bot, you can configure your own wheel strategy including HOLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HOLX
- Rev/Share 18.005
- Book/Share 21.5879
- PB 3.1263
- Debt/Equity 0.5209
- CurrentRatio 3.5547
- ROIC 0.0743
- MktCap 15011077342.0
- FreeCF/Share 4.3608
- PFCF 15.3456
- PE 27.1747
- Debt/Assets 0.2864
- DivYield 0
- ROE 0.1151
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | HOLX | Argus | Hold | Buy | -- | $80 | Aug. 18, 2025 |
| Upgrade | HOLX | RBC Capital Mkts | Sector Perform | Outperform | -- | $87 | Aug. 6, 2025 |
| Upgrade | HOLX | Citigroup | Neutral | Buy | -- | $80 | July 9, 2025 |
| Reiterated | HOLX | Needham | -- | Hold | -- | -- | May 27, 2025 |
| Downgrade | HOLX | Argus | Buy | Hold | -- | -- | March 3, 2025 |
| Downgrade | HOLX | Leerink Partners | Outperform | Market Perform | $80 | $75 | Feb. 6, 2025 |
| Downgrade | HOLX | Needham | Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | HOLX | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Reiterated | HOLX | Needham | -- | Buy | -- | $90 | Dec. 10, 2024 |
| Initiation | HOLX | Jefferies | -- | Hold | -- | $85 | Dec. 10, 2024 |
News
HOLX vs. IDXX: Which Stock Is the Better Value Option?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Instruments stocks have likely encountered both Hologic (HOLX) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
Read More
Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
Volition Signs Co-Marketing and Services Agreement with Hologic
Published: September 29, 2025 by: PRNewsWire
Sentiment: Neutral
HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-marketing of Volition's Nu.Q® Discover service.
Read More
Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm
Published: September 29, 2025 by: PRNewsWire
Sentiment: Neutral
HAUPPAUGE, N.Y. , Sept. 29, 2025 /PRNewswire/ -- Minicarm.com, a leading provider of imaging solutions for orthopedic and surgical practices, is proud to announce that it has secured an allocation of the Hologic Fluoroscan® Insight™ FD Mini C-Arm for resale in the United States.
Read More
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic set to end sales of Fluoroscan InSight FD in 2025 but sees strong momentum from DXA systems and broader business growth.
Read More
HOLX vs. TMO: Which Diagnostic Giant Is the Stronger Buy Today?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Diagnostic leaders Hologic and Thermo Fisher post raised outlooks, acquisitions and strong product momentum.
Read More
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hologic's Strong International Traction to Continue Despite Headwinds
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX's global push shows strength, with surgical growth and rising diagnostics use offsetting near-term challenges.
Read More
Hologic (HOLX) Soars 7.7%: Is Further Upside Left in the Stock?
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Breast Health revival, fueled by AI, leadership shifts and product upgrades, is setting up a growth rebound.
Read More
Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.
Read More
Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Hologic, Inc. (NASDAQ:HOLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Stephen MacMillan - Chairman, CEO & President Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Michael Matson - Needham & Company, LLC, Research Division Presentation Kallum Titchmarsh Equity Analyst Okay. Thank you, everyone.
Read More
Hologic's Panther Fusion Signals More Molecular Diagnostics Upside
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Panther Fusion expands its diagnostics menu, fueling assay growth and unlocking more upside in molecular testing.
Read More
The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.
Read More
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Read More
HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Two MedTech giants, one clear winner. Boston Scientific's momentum outpaces Hologic's cautious rise.
Read More
Here's Why Hologic (HOLX) is a Strong Value Stock
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
Read More
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
Read More
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Read More
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Interpreting Hologic (HOLX) International Revenue Trends
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Read More
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Read More
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Read More
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Negative
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Read More
About Hologic, Inc. (HOLX)
- IPO Date 1990-03-01
- Website https://www.hologic.com
- Industry Medical - Instruments & Supplies
- CEO Stephen P. MacMillan
- Employees 7063